Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Matthew J, Elder"'
Autor:
Alba Matas-Céspedes, Jean-Martin Lapointe, Matthew J. Elder, Gareth J. Browne, Simon J. Dovedi, Lolke de Haan, Shaun Maguire, Richard Stebbings
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionHumanized mice are emerging as valuable models to experimentally evaluate the impact of different immunotherapeutics on the human immune system. These immunodeficient mice are engrafted with human cells or tissues, that then mimic the hum
Externí odkaz:
https://doaj.org/article/11c5d1d250e84b188c37cec9021c84c8
Autor:
Stefanie R. Mullins, John P. Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J. Elder, John Swales, Elina Timosenko, Zachary Cooper, Simon J. Dovedi, Andrew J. Leishman, Nadia Luheshi, James Elvecrog, Ashenafi Tilahun, Richard Goodwin, Ronald Herbst, Mark A. Tomai, Robert W. Wilkinson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-18 (2019)
Abstract Background Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation may be required to
Externí odkaz:
https://doaj.org/article/664a845e229648008b22d687ebf6b261
Autor:
Matthew J. Elder, Steve J. Webster, Timothy J. Fitzmaurice, Aran S. D. Shaunak, Martin Steinmetz, Ronnie Chee, Ziad Mallat, E. Suzanne Cohen, David L. Williams, J. S. Hill Gaston, Jane C. Goodall
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Thymic stromal lymphopoietin (TSLP) is a functionally pleotropic cytokine important in immune regulation, and TSLP dysregulation is associated with numerous diseases. TSLP is produced by many cell types, but has predominantly been characterized as a
Externí odkaz:
https://doaj.org/article/d37c0112f5e9441b8aa4a1a774e80bea
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
Supplementary Materials and Methods, and Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238b4ab5c831dd6063dffdf564c8ad3c
https://doi.org/10.1158/2159-8290.22540037
https://doi.org/10.1158/2159-8290.22540037
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca7eaed273b219faf1bb63ec9cf8694
https://doi.org/10.1158/2159-8290.c.6549263
https://doi.org/10.1158/2159-8290.c.6549263
Autor:
Matthew J. Elder, Steve J. Webster, Ronnie Chee, David L. Williams, J. S. Hill Gaston, Jane C. Goodall
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Dectin-1/CLEC7A is a pattern recognition receptor that recognizes β-1,3 glucans, and its stimulation initiates signaling events characterized by the production of inflammatory cytokines from human dendritic cells (DCs) required for antifungal immuni
Externí odkaz:
https://doaj.org/article/7b61fa02b4424390890f997b33134bad
Autor:
Steve J Webster, Sven Brode, Lou Ellis, Timothy J Fitzmaurice, Matthew J Elder, Nelson O Gekara, Panagiotis Tourlomousis, Clare Bryant, Simon Clare, Ronnie Chee, Hill J S Gaston, Jane C Goodall
Publikováno v:
PLoS Pathogens, Vol 13, Iss 6, p e1006383 (2017)
The innate immune system is a critical component of host defence against microbial pathogens, but effective responses require an ability to distinguish between infectious and non-infectious insult to prevent inappropriate inflammation. Using the impo
Externí odkaz:
https://doaj.org/article/cc7ab21c35704bf99075bec68f1688a5
Autor:
Bo Wang, Frances Neal, Arthur Lewis, Kapil Vashisht, Deepa S. Subramaniam, Des C. Jones, Sumati Hasani, Daniel J. Freeman, Chunning Yang, Lorraine Irving, Michael G. Overstreet, Gareth J. Browne, Suzanne I. Sitnikova, James Hair, Robert W. Wilkinson, Yaya Wang, Ben Tran, Ikbel Achour, James Dodgson, Shelby D. Gainer, Xiaofang Jin, Seock-Ah Im, William F Dall'Acqua, Yariv Mazor, Godfrey Rainey, Asis Palazon, Anna Hansen, Yanli Wu, Matthew J. Elder, Stacy Kentner, Aleksandra D. Toloczko, Michelle Morrow, Murray Thomas Vincent, Simon J. Dovedi, Kathy Mulgrew
Publikováno v:
Cancer Discovery. 11:1100-1117
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca36b45e55f3b372d826ed6a15c12039
https://doi.org/10.1158/2159-8290.cd-20-1445
https://doi.org/10.1158/2159-8290.cd-20-1445
Autor:
Amy Shergold, Shannon Burke, Robert W. Wilkinson, Matthew J. Elder, Hong Jin, Justine Whitworth, James Harper, Danielle Carroll, Xing Cheng
Publikováno v:
Cancer Immunology, Immunotherapy
Oncolytic virus (OV) therapy is an emerging approach with the potential to redefine treatment options across a range of cancer indications and in patients who remain resistant to existing standards of care, including immuno-oncology (IO) drugs. MEDI5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68275b8ee20c1e30df96fbcd5458c427
http://europepmc.org/articles/PMC7230062
http://europepmc.org/articles/PMC7230062
Autor:
Simon J, Dovedi, Matthew J, Elder, Chunning, Yang, Suzanne I, Sitnikova, Lorraine, Irving, Anna, Hansen, James, Hair, Des C, Jones, Sumati, Hasani, Bo, Wang, Seock-Ah, Im, Ben, Tran, Deepa S, Subramaniam, Shelby D, Gainer, Kapil, Vashisht, Arthur, Lewis, Xiaofang, Jin, Stacy, Kentner, Kathy, Mulgrew, Yaya, Wang, Michael G, Overstreet, James, Dodgson, Yanli, Wu, Asis, Palazon, Michelle, Morrow, Godfrey J, Rainey, Gareth J, Browne, Frances, Neal, Thomas V, Murray, Aleksandra D, Toloczko, William, Dall'Acqua, Ikbel, Achour, Daniel J, Freeman, Robert W, Wilkinson, Yariv, Mazor
Publikováno v:
Cancer discovery. 11(5)
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9cee0afaa71445587217670a975d51b1
https://pubmed.ncbi.nlm.nih.gov/33947716
https://pubmed.ncbi.nlm.nih.gov/33947716